Healthcare -
Biotechnology - NASDAQ - US
$ 3.1
7.27 %
$ 4.78 M
Market Cap
-1.21
P/E
1. INTRINSIC VALUE
Balance Sheet
Xenetic Biosciences, Inc.
| Current Assets | 6.59 M |
| Cash & Short-Term Investments | 6.17 M |
| Receivables | 0 |
| Other Current Assets | 422 K |
| Non-Current Assets | 314 K |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 314 K |
| Current Liabilities | 894 K |
| Accounts Payable | 284 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 611 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Xenetic Biosciences, Inc.
| Revenue | 2.5 M |
| Cost Of Revenue | 0 |
| Gross Profit | 2.5 M |
| Operating Expenses | 6.7 M |
| Operating Income | -4.2 M |
| Other Expenses | -244 K |
| Net Income | -3.96 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Xenetic Biosciences, Inc.
| Net Income | -3.96 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 172 K |
| Change in Working Capital | 971 K |
| Others | 886 K |
| Free Cash Flow | -2.82 M |
Wall Street Analysts Price Targets
Xenetic Biosciences, Inc.
XBIO has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
XBIO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Xenetic Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Watch the "What This Means" video here FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment . As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent poster presentation titled, "DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma," which was presented at the at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
accessnewswire.com
- 1 month ago
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.
accessnewswire.com
- 1 month ago
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma FRAMINGHAM, MA / ACCESS Newswire / March 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024. Recent Highlights Extended its collaborations with the University of Virginia and Scripps Research through 2025; Entered into a Clinical Trial Services Agreement with PeriNess Ltd.
accessnewswire.com
- 2 months ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, " DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma ," was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
accessnewswire.com
- 2 months ago
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. Details for the presentation are as follows: Abstract Number: 123 Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute Date & Time: Wednesday, March 12, 2025 at 5:10 p.m.
accessnewswire.com
- 2 months ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment As part of the segment, Dr. Bissonnette discussed the Company's recently announced extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform. The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
accesswire.com
- 5 months ago
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins.
accesswire.com
- 5 months ago
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies.
accesswire.com
- 5 months ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment. As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent positive data demonstrating DNase I significantly improves efficacy of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma (CRC) which was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
accesswire.com
- 5 months ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, " The synergistic action of DNase I and CAR T cells enhances the therapeutic efficacy of adoptive immunotherapy in the syngeneic murine metastasis model ," was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer, held November 17-20, 2024, in Boston.
accesswire.com
- 5 months ago
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors Strategic focus on exploratory investigator-initiated studies with institutional partners Ended the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024. "Over the course of the past quarter, we have continued to make progress advancing our DNase platform.
accesswire.com
- 6 months ago
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Data presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma (CRC) tumors FRAMINGHAM, MA / ACCESSWIRE / November 12, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced the presentation of positive preclinical data. The poster titled, " DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC ," was presented byReid Bissonnette, Ph.D.
accesswire.com
- 6 months ago
8. Profile
Summary
Xenetic Biosciences, Inc. XBIO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.78 M
Dividend Yield
0.00%
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Contact
40 Speen Street, Framingham, MA, 01701
https://www.xeneticbio.com
IPO
Date
June 30, 2016
Employees
2
Officers
Mr. James F. Parslow
Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary